Abstract
Research has proven that blood pressure is an important modifiable risk factor for diabetic retinopathy and that lowering high blood pressure significantly reduces the development and progression of retinopathy in both type 1 and type 2 diabetic patients. The renin-angiotensin-system (RAS) has been shown to become activated in diabetes. Hyperglycemia stimulates the angiotensin AT1-receptor and downstream chains of events resulting in diabetic end organ damage. Pharmacological RAS inhibition may thus be a beneficial therapeutic strategy in the management of diabetic retinopathy. The present review article details therapeutic RAS inhibition in diabetic retinopathy with an emphasis on recently published evidence. Future research on the potential effects of RAS blockade will be important while using these drugs as adjuncts in the treatment of diabetic retinopathy.
Keywords: Blood pressure, diabetes mellitus, renin-angiotensin-system, diabetic retinopathy, DIRECT, NAVIGATOR, DREAM, EUCLID
Current Pharmaceutical Biotechnology
Title: The Therapeutic Implications of Renin-Angiotensin System Blockade in Diabetic Retinopathy
Volume: 12 Issue: 3
Author(s): V. Swetha E. Jeganathan
Affiliation:
Keywords: Blood pressure, diabetes mellitus, renin-angiotensin-system, diabetic retinopathy, DIRECT, NAVIGATOR, DREAM, EUCLID
Abstract: Research has proven that blood pressure is an important modifiable risk factor for diabetic retinopathy and that lowering high blood pressure significantly reduces the development and progression of retinopathy in both type 1 and type 2 diabetic patients. The renin-angiotensin-system (RAS) has been shown to become activated in diabetes. Hyperglycemia stimulates the angiotensin AT1-receptor and downstream chains of events resulting in diabetic end organ damage. Pharmacological RAS inhibition may thus be a beneficial therapeutic strategy in the management of diabetic retinopathy. The present review article details therapeutic RAS inhibition in diabetic retinopathy with an emphasis on recently published evidence. Future research on the potential effects of RAS blockade will be important while using these drugs as adjuncts in the treatment of diabetic retinopathy.
Export Options
About this article
Cite this article as:
Swetha E. Jeganathan V., The Therapeutic Implications of Renin-Angiotensin System Blockade in Diabetic Retinopathy, Current Pharmaceutical Biotechnology 2011; 12 (3) . https://dx.doi.org/10.2174/138920111794480615
DOI https://dx.doi.org/10.2174/138920111794480615 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Diabetes Therapy: Novel Patents Targeting the Glucose-Induced Insulin Secretion
Recent Patents on DNA & Gene Sequences Role of Vitamin D in Vascular Complications and Vascular Access Outcome in Patients with Chronic Kidney Disease
Current Medicinal Chemistry Bone Disease in Diabetes
Current Diabetes Reviews A Possible Target of Antioxidative Therapy for Diabetic Vascular Complications-Vascular NAD(P)H Oxidase
Current Medicinal Chemistry Chronic Kidney Disease and Urological Disorders: An Overview
Current Signal Transduction Therapy Losartan Chemistry and Its Effects via AT1 Mechanisms in the Kidney
Current Medicinal Chemistry Fetuin-A: A Multifunctional Protein
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Regulation of Angiotensin II Receptor Expression
Current Pharmaceutical Design Recent Advances in Management of Diabetic Macular Edema
Current Diabetes Reviews The Application of Micro-Analytical Techniques to Biomedical Analysis
Current Pharmaceutical Analysis Early Urinary Markers for Diabetic and Other Kidney Diseases
Current Drug Targets Diabetes-induced Proteome Changes Throughout Development
Endocrine, Metabolic & Immune Disorders - Drug Targets Emerging Roles for Metabolic Engineering - Understanding Primitive and Complex Metabolic Models and Their Relevance to Healthy and Diseased Kidney Podocytes
Current Chemical Biology Transdermal Innovations in Diabetes Management
Current Diabetes Reviews Is Atorvastatin Superior to Other Statins? Analysis of the Clinical Trials with Atorvastatin Having Cardiovascular Endpoints
Reviews on Recent Clinical Trials Aminoacid Support in the Prevention of Diabetes and Diabetic Complications
Current Protein & Peptide Science Endothelin-1 Signaling in Vascular Physiology and Pathophysiology
Current Vascular Pharmacology One Special Question to Start with: Can HIF/NFkB be a Target in Inflammation?
Endocrine, Metabolic & Immune Disorders - Drug Targets Beneficial Extracardiac Effects of Cardiovascular Medications
Current Cardiology Reviews Various Non-Injectable Delivery Systems for the Treatment of Diabetes Mellitus
Endocrine, Metabolic & Immune Disorders - Drug Targets